Thats not what I'm stating.. Personally I dont think they would be able to come to a deal that both parties agree to.
How much would Amgen pay for licensing of one indication in one region? My guess is they would want a lot more use of Bisantrene (who wouldn't!), and RAC are not in the position they want to be in to be making that deal. That's all.
Ann: Race Strategic Update August 2023, page-592
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
-0.055(3.77%) |
Mkt cap ! $236.2M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.40 | $157.9K | 111.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3980 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 2613 | 2 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.40 |
Change
-0.055 ( 2.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.44 | $1.40 | 6146 | ||
| Last updated 15.46pm 28/05/2024 ? | |||||
| RAC (ASX) Chart |